Evinacumab not checked
Regeneron · REGN1500 · R1500
FollowEvery change as it happens, and a Monday email
Trials
1 active
7 in total
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Diabetic Kidney Disease (DKD)
- Main trialPhase 2
- “This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times”In the company’s words, NCT07271186 on ClinicalTrials.gov
- Other names
- REGN1500 · Evkeeza · R1500
Other drugs for Diabetic Kidney Disease (DKD)
- WAL0921Walden Biosciences · Phase 2
- R3R01River 3 Renal Corp. · Phase 2
- IsuzinaxibAptabio Therapeutics, Inc. · Phase 2
- Umbilical Cord Mesenchymal Stem CellsPT. Prodia Stem Cell Indonesia · Phase 1/2
- ALN-ANG3Regeneron · Phase 2
- AtrasentanNovartis · Phase 2
Coming up1
- 13 Oct 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 13 Oct 2028 | Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease | |
| Phase 3Completed | 10 Jun 2019 | Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | |
| Phase 3Completed | 31 Jan 2022 | Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia | |
| Phase 3Completed | 13 Apr 2023 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | |
| Phase 2Completed | 17 Dec 2019 | Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis | |
| Phase 2Completed | 22 May 2020 | Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia | |
| Phase 2Terminated | 15 Feb 2023 | Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026